Dextran-based Drug Delivery Approaches for Lung Diseases: A Review.

Manisha Kumari, Sanyam Sharma, Navjot Kanwar, Subh Naman, Ashish Baldi
{"title":"Dextran-based Drug Delivery Approaches for Lung Diseases: A Review.","authors":"Manisha Kumari, Sanyam Sharma, Navjot Kanwar, Subh Naman, Ashish Baldi","doi":"10.2174/0115672018267737231116100812","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory disorders, such as tuberculosis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, lung cancer, and pulmonary inflammation, are among the most prevalent ailments in today's world. Dextran, an exopolysaccharide formed by <i>Leuconostoc mesenteroides</i> (slimeproducing bacteria), and its derivatives are investigated for several therapeutic utilities. Dextranbased drug delivery system can become an innovative strategy in the treatment of several respiratory ailments as it offers numerous advantages, such as mucolytic action, airway hydration, antiinflammatory properties, and radioprotective effect as compared to other polysaccharides. Being biocompatible, flexible hydrophilic nature, biodegradable, tasteless, odourless, non-mutagenic, watersoluble and non-toxic edible polymer, dextran-based drug delivery systems have been explored for a wide range of therapeutic applications, especially in lungs and respiratory diseases. The present article comprehensively discusses various derivatives of dextran with their attributes to be considered for drug delivery and extensive therapeutic benefits, with a special emphasis on the armamentarium of dextran-based formulations for the treatment of respiratory disorders and associated pathological conditions. The information provided will act as a platform for formulation scientists as important considerations in designing therapeutic approaches for lung and respiratory diseases. With an emphasis on lung illnesses, this article will offer an in-depth understanding of dextran-based delivery systems in respiratory illnesses.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018267737231116100812","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Respiratory disorders, such as tuberculosis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, lung cancer, and pulmonary inflammation, are among the most prevalent ailments in today's world. Dextran, an exopolysaccharide formed by Leuconostoc mesenteroides (slimeproducing bacteria), and its derivatives are investigated for several therapeutic utilities. Dextranbased drug delivery system can become an innovative strategy in the treatment of several respiratory ailments as it offers numerous advantages, such as mucolytic action, airway hydration, antiinflammatory properties, and radioprotective effect as compared to other polysaccharides. Being biocompatible, flexible hydrophilic nature, biodegradable, tasteless, odourless, non-mutagenic, watersoluble and non-toxic edible polymer, dextran-based drug delivery systems have been explored for a wide range of therapeutic applications, especially in lungs and respiratory diseases. The present article comprehensively discusses various derivatives of dextran with their attributes to be considered for drug delivery and extensive therapeutic benefits, with a special emphasis on the armamentarium of dextran-based formulations for the treatment of respiratory disorders and associated pathological conditions. The information provided will act as a platform for formulation scientists as important considerations in designing therapeutic approaches for lung and respiratory diseases. With an emphasis on lung illnesses, this article will offer an in-depth understanding of dextran-based delivery systems in respiratory illnesses.

基于葡聚糖的肺部疾病给药方法:综述。
肺结核、囊性纤维化、慢性阻塞性肺病、哮喘、肺癌和肺部炎症等呼吸系统疾病是当今世界最普遍的疾病之一。右旋糖酐是一种由肠道黏液产生菌(Leuconostoc mesenteroides)形成的外多糖,其衍生物被研究用于多种治疗用途。与其他多糖相比,葡聚糖具有多种优势,如粘液溶解作用、气道水合作用、抗炎特性和放射保护作用,因此,以葡聚糖为基础的给药系统可以成为治疗多种呼吸系统疾病的创新策略。葡聚糖是一种具有生物相容性、柔性亲水性、可生物降解、无味、无臭、无致突变性、水溶性和无毒的可食用聚合物,以葡聚糖为基础的给药系统已被广泛应用于治疗领域,尤其是肺部和呼吸系统疾病。本文全面论述了葡聚糖的各种衍生物,以及它们在给药方面的特性和广泛的治疗效果,特别强调了以葡聚糖为基础的配方在治疗呼吸系统疾病和相关病症方面的作用。所提供的信息将为制剂科学家提供一个平台,作为设计肺部和呼吸系统疾病治疗方法的重要考虑因素。本文将以肺部疾病为重点,深入介绍基于葡聚糖的给药系统在呼吸系统疾病中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信